7315-67-5Relevant articles and documents
Bio-based crotonic acid from polyhydroxybutyrate: synthesis and photocatalyzed hydroacylation
Fagnoni, Maurizio,Galletti, Paola,Jorea, Alexandra,Parodi, Adriano,Ravelli, Davide,Samorì, Chiara,Torri, Cristian
supporting information, p. 3420 - 3427 (2021/05/21)
A novel thermolytic distillation process was developed to depolymerize polyhydroxybutyrate (PHB) for the selective production of crotonic acid. The conditions adopted (170 °C, 150 mbar) were applied to pure PHB and PHB-enriched bacteria containing 60 and 30% of PHB, giving a recovery of crotonic acid of 92, 78 and 58%, respectively. The high efficiency of the developed process poses the basis for a drop-in production of bio-based crotonic acid, whose versatility as a platform chemical has been investigated through a photochemical approach. The photocatalytic addition (promoted by tetrabutylammonium decatungstate - TBADT) of aliphatic and aromatic aldehydes to crotonic acid took place under solar-simulated light irradiation. TBADT triggered thein situformation of valuable acyl radicals from the corresponding aldehydes, thus inducing the desired hydroacylationviaradical conjugate addition. Notably, the functionalization took place in a satisfactory yield quite independently of the adopted sample of crotonic acid (whether commercial or bio-based).
THERAPEUTIC AGENT FOR DIABETES
-
, (2008/06/13)
A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.
Stereoselective Reduction of γ-Oxo-γ-phenylbutanoic Acids
Frenette, R.,Kakushima, M.,Zamboni, R.,Young, R. N.,Verhoeven, T. R.
, p. 304 - 307 (2007/10/02)
-
